Filing Overview
Regencell Bioscience Holdings Limited filed a Form 6-K on June 5, 2023, covering the month of June 2023. The company is a foreign private issuer that files annual reports on Form 20-F.
Material Event
All directors and employees who had previously received stock options agreed to extend their lock-up undertakings for an additional six months, through January 20, 2024. Their shares will remain subject to the lock-up until that date.
The extension follows prior lock-up undertakings that were scheduled to expire on July 20, 2023. The form of the lock-up undertaking was filed as Exhibit 99.1.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other financial metrics.
Outlook, Risks, and Unusual Items
The extended lock-up may reduce the near-term availability of shares held by directors and employees for sale, but the filing does not provide management commentary regarding market impact, future share sales, business outlook, or contingencies.
Investor Verification Items
- Verify the terms and scope of the lock-up undertaking in Exhibit 99.1.
- Confirm the January 20, 2024 expiration date and which directors, employees, and shares are covered.
- Review the company’s latest Form 20-F and subsequent Form 6-K filings for financial results, cash resources, operating developments, and any changes to the lock-up arrangements.